The authors monitored the clinical course of their patients with melanoma between 1984 and 2018 based on the digitalized documentation system of their hospital. They analyzed the treated and non-treated cases underguidance of a dermatologist-pathologist-oncologist in a single-center setting.
Altogether 867 cases (450 women and 417 men) were examined starting at the time of primary tumor removal in a retrospective way. Distribution of gender and age, tumor stages and body regions by separating genders were examined.
The authors also assessed asymptomatic period till tumor progression, mortality data, the duration and effect of adjuvant low-, intermediate and high dose interferonα-2b immunotherapy.
Those patients with arising lymph node metastasis who received low or intermediate dose immunotherapy have experienced significantly longer tumor free period than those who were treated by the high dose. In both treated groups the median value of disease free interval was higher as compared to the “only observed group”. These results of the long term follow-up may contribute to the more accurate evaluation of melanoma and of the interferon therapy in Hungary as part and representing state of Central European region.

During the past decades, emerging unrealistic body expectations are seen in western societies. Several negative consequences are linked to this phenomenon, one being the elevated incidence of body dysmorphic disorder (BDD) cases.
Certain reports indicate that the incidence of BDD may be as high as 9-15% among dermatological patients. Despite the relatively high incidence, dermatologists’ knowledge regarding BDD is incomplete, and the treatment of these disorders can be challenging. It is also hardly known that BDD may be related to other fairly common psychodermatological diseases such as trichotillomania and acne excoriée. Here, we review the main characteristics and treatment options of BDD, and present related psychodermatological conditions, which are classified into the „obsessive-compulsive and related disorders” in DSM-5, the current psychiatric diagnostic system.

This paper gives a detailed summary of the mucocutaneous side effects that is known to develop during the cytoreductive therapy with hydroxyurea in myeloproliferative hematologic diseases.

The discovery of IL-17 producing TH17 cells revolutionized our concept on immune- and T-cell mediated diseases, including psoriasis. Driven by IL-23, TH17 cells produce large amounts of IL-17, which, in turn, leads to a self-perpetuating inflammatory loop in skin, and results in epidermal hyperplasia and cellular infiltration. Thus, targeting the IL-23/IL-17 pathway has become one of the most promising candidates for treating psoriasis. Recently, after the introduction of IL-17 inhibitors in clinical practice, IL-23 inhibitors proved to be one of the most effective treatment form plaque type psoriasis, leading to a paradigm shift in our therapeutic approach. This article introduces the pathogenetic role IL-23 plays in psoriasis, and summarizes the recent clinical results achieved by the new IL-23 inhibitors (guselkumab,
risankizumab, tildrakizumab).